Redeye provides its initial take on Surgical Science’s Q1 2025 report, which mostly beat our estimates. We judge that notable positives from the report include strong Educational Products sales and margins exceeding our projections by c1-3%-points despite one-off costs related to recent M&A. Notable negatives include Surgical Science lowering its financial targets. However, we believe this was largely expected.
LÄS MER
